[Immunsuppressive treatment of multiple sclerosis. 2. Critical review of general results (author's transl)].
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D002908:Chronic Disease; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008134:Long-Term Care; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy*; D009186:Myelin Sheath; D009419:Nerve Tissue Proteins / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011379:Prognosis; D014020:Tissue Extracts / Q000627:therapeutic use
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D009419:Nerve Tissue Proteins; D014020:Tissue Extracts; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D001379:Azathioprine; D008727:Methotrexate
Immunsuppressive Therapie der Multiplen Sklerose. 2. Kritischer Bericht über allgemeine Erfahrungen